Figure 2
From: Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs
Evaluation of prognostic ability of the model based on clinical information. (a) One-year ROC curve in the training set. (b) One-year ROC curves in the test set. (c) Analysis of survival differences between the distinct risk populations in the training set. (d) Survival difference analysis between the distinct risk groups in the test set.
